| Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. | |
| | |
MedLine Citation:
|
PMID: 22212572 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
This is an excellent time for patients with hepatitis C virus infection who have failed past treatment with standard of care (SOC) peginterferon (PEG-IFN) and ribavirin (RBV). New treatments have been shown to increase sustained virological response (SVR) rates. Previous relapsers and those with some responsiveness to interferon will clearly benefit from protease inhibitor-based therapy. Patients with little interferon response may not be suited for these regimens, but can be treated by careful selection on a case-by-case basis. Resistance needs to be carefully monitored as these newer and more potent drugs are added to IFN and RBV backbone drugs. Adverse events will be more frequent and will require special attention. |
| | |
Authors:
|
Bruce R Bacon; Omer Khalid |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 32 Suppl 1 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: England |
Other Details:
|
Languages: eng Pagination: 51-3 Citation Subset: IM |
Copyright Information:
|
© 2012 John Wiley & Sons A/S. |
Affiliation:
|
Division of Gastroenterology & Hepatology, Saint Louis University School of Medicine, St. Louis, MO, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-r...
Next Document: Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?